Archive:
Feb 5, 2025, 12:00 AM
Benefit of adjuvant pembrolizumab on recurrence-free survival and distant metastasis-free survival in patients with resected high-risk stage II melanoma, irrespective of primary tumor location
Background: Previous results from the KEYNOTE-716 trial demonstrated significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with adjuvant pembrolizumab versu…
Melanomas associated with pre-existing nevi appear to be an independent favorable prognostic factor for recurrence and survival
Background: Although most melanomas develop de novo, about 30% are nevus-associated melanomas, where the prognostic value is unclear. Our study aimed to determine whether nevus-associated melanoma is …